公开(公告)号：US12226400B2

公开(公告)日：2025-02-18

申请号：US17264982

申请日：2019-07-31

Applicant: UNIVERSITY OF PITTSBURGH-OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION

Inventor： Elias Aizenman ,  Carlos Jaime Camacho

IPC: A61K31/4155 ,  A61K31/4178 ,  A61K31/428 ,  A61K31/4409 ,  A61K31/506 ,  A61K31/53 ,  A61P25/28

Abstract: Disclosed herein are small molecule compounds capable of disrupting Kv2.1-syntaxin binding. The compounds are useful for treating a variety of neurological disorders, diseases, and injuries.

公开(公告)号：US12214146B2

公开(公告)日：2025-02-04

申请号：US17118143

申请日：2020-12-10

Applicant: Biocoat, Incorporated

Inventor： William James Work ,  Raymond Joseph Gould ,  Dhruv Patel ,  Robert W Hergenrother

IPC: A61M25/10 ,  A61K31/145 ,  A61K31/155 ,  A61K31/165 ,  A61K31/166 ,  A61K31/167 ,  A61K31/437 ,  A61K31/4409 ,  A61K31/473 ,  A61K31/502 ,  A61K31/505 ,  A61K31/506 ,  A61K31/52 ,  A61K31/53 ,  A61K31/5377 ,  A61K31/655 ,  A61K31/7008 ,  A61K31/7048 ,  A61K31/7076 ,  A61K31/708 ,  A61L29/08 ,  A61L29/16 ,  B05D5/00 ,  B05D7/00

Abstract: The present invention is an implantable medical device comprising (i) a base coat layer having an inner and outer surface, the inner surface of the base coat layer contacting the implantable medical device; (ii) a top-coat layer of a hydrophilic polymer chemically crosslinked and covalently bonded to the outer surface of the base coat layer, the hydrophilic polymer comprising an anionic polyelectrolyte; and (iii) an amount of a hydrophilic cationic drug agent added to the top-coat layer sufficient to provide an effective dosage of the drug agent for delivery to a patient, whereby the hydrophilic cationic drug agent is initially adsorbed into the anionic polyelectrolyte of the top-coat layer and the hydrophilic cationic drug agent having a release rate after the medical device is implanted within a patient's body.

公开(公告)号：US12178791B2

公开(公告)日：2024-12-31

申请号：US17265402

申请日：2019-08-02

Applicant: Syntara Limited

Inventor： Alison Dorothy Findlay ,  Craig Ivan Turner ,  Mandar Deodhar ,  Jonathan Stuart Foot ,  Wolfgang Jarolimek ,  Wenbin Zhou ,  Alberto Buson ,  Angelique Elsa Greco

IPC: C07D209/08 ,  A61K31/145 ,  A61K31/18 ,  A61K31/4409 ,  A61K31/47 ,  A61P17/02 ,  A61P19/04 ,  A61P35/00 ,  A61P35/04 ,  C07C311/29 ,  C07C317/32 ,  C07D213/71 ,  C07D215/36 ,  C07D277/64

Abstract: The present invention relates to novel compounds which are capable of inhibiting certain amine oxidase enzymes. These compounds are useful for treatment of a variety of indications, e.g., fibrosis, cancer and/or angiogenesis in human subjects as well as in pets and livestock. In addition, the present invention relates to pharmaceutical compositions containing these compounds, as well as various uses thereof.

公开(公告)号：US12168021B2

公开(公告)日：2024-12-17

申请号：US17845688

申请日：2022-06-21

Applicant: INSMED INCORPORATED

Inventor： Gina Eagle ,  Renu Gupta

IPC: A61K31/7036 ,  A61K9/00 ,  A61K9/127 ,  A61K31/133 ,  A61K31/407 ,  A61K31/4375 ,  A61K31/4409 ,  A61K31/4709 ,  A61K31/496 ,  A61K31/5383 ,  A61K31/546 ,  A61K31/65 ,  A61K31/7048 ,  A61K31/7052 ,  A61K45/06 ,  A61P31/04

Abstract: Provided herein are methods for treating a pulmonary infection in a patient in need thereof, for example, a nontuberculous mycobacterial pulmonary infection for at least one treatment cycle. The method comprises administering to the lungs of the patient a pharmaceutical composition comprising a liposomal complexed aminoglycoside comprising a lipid component comprising electrically neutral lipids and an aminoglycoside. Administration comprises aerosolizing the pharmaceutical composition to provide an aerosolized pharmaceutical composition comprising a mixture of free aminoglycoside and liposomal complexed aminoglycoside, and administering the aerosolized pharmaceutical composition via a nebulizer to the lungs of the patient. The methods provided herein result in a change from baseline on the semi-quantitative scale for mycobacterial culture for a treated patient, and/or NTM culture conversion to negative during or after the administration period.

公开(公告)号：US20240342175A1

公开(公告)日：2024-10-17

申请号：US18617800

申请日：2024-03-27

Applicant: Howard Mitz

Inventor： Howard Mitz

IPC: A61K31/517 ,  A61K31/16 ,  A61K31/167 ,  A61K31/192 ,  A61K31/22 ,  A61K31/352 ,  A61K31/381 ,  A61K31/40 ,  A61K31/401 ,  A61K31/428 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/472 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K31/65 ,  A61K35/60 ,  A61K36/00 ,  A61K38/57 ,  A61P25/00

CPC classification number: A61K31/517 ,  A61K31/16 ,  A61K31/167 ,  A61K31/192 ,  A61K31/22 ,  A61K31/352 ,  A61K31/381 ,  A61K31/40 ,  A61K31/401 ,  A61K31/428 ,  A61K31/437 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/472 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/541 ,  A61K31/551 ,  A61K31/65 ,  A61K35/60 ,  A61K36/00 ,  A61K38/57 ,  A61P25/00

Abstract: The present invention provides methods and compositions for treating synaptic dysfunction and spinal cord injuries comprising, for example, the administration of a compound that increases the level of PZP in vivo.

公开(公告)号：US12115171B2

公开(公告)日：2024-10-15

申请号：US17836836

申请日：2022-06-09

Applicant: Massachusetts Institute of Technology

Inventor： Michael B. Yaffe ,  Jesse C. Patterson

IPC: A61K31/58 ,  A61K31/337 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/519 ,  A61K31/567 ,  A61K31/573 ,  A61K31/575 ,  A61K45/06

CPC classification number: A61K31/58 ,  A61K31/337 ,  A61K31/4409 ,  A61K31/4439 ,  A61K31/496 ,  A61K31/519 ,  A61K31/567 ,  A61K31/573 ,  A61K31/575 ,  A61K45/06 ,  A61K31/567 ,  A61K2300/00 ,  A61K31/575 ,  A61K2300/00 ,  A61K31/4439 ,  A61K2300/00 ,  A61K31/58 ,  A61K2300/00 ,  A61K31/496 ,  A61K2300/00 ,  A61K31/519 ,  A61K2300/00 ,  A61K31/4409 ,  A61K2300/00

Abstract: Pharmaceutical compositions including an effective amount of an antiandrogen or androgen antagonist in combination with a Plk inhibitor and methods of use thereof for treating cancer are disclosed. Administration of the combination of the active agents can be effective to reduce cancer cell proliferation or viability in a subject with cancer to the same degree, or a greater degree than administering to the subject the same amount of either active agent alone. The active agents can be administered together or separately. Methods of selecting and treating subjects with cancers, particular prostate cancers including castration resistant prostate cancer, breast cancers, particularly androgen receptor positive breast cancers, and pancreatic cancers are also provided.

公开(公告)号：US20240307537A1

公开(公告)日：2024-09-19

申请号：US18451632

申请日：2023-08-17

Applicant: Omeros Corporation

Inventor： Michael Cicirelli ,  Neil S. Cutshall ,  Gregory A. Demopulos ,  George A. Gaitanaris ,  Marc A. Gavin ,  Alexander Gragerov ,  Thomas L. Little ,  Rene Onrust

IPC: A61K39/00 ,  A61K31/17 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4409 ,  A61K31/473 ,  A61K31/495 ,  A61K31/496 ,  A61K31/502 ,  A61K31/506 ,  A61K31/519 ,  A61K31/522 ,  A61K31/53 ,  A61K31/55 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  G01N33/574

CPC classification number: A61K39/4643 ,  A61K31/17 ,  A61K31/341 ,  A61K31/381 ,  A61K31/4409 ,  A61K31/473 ,  A61K31/495 ,  A61K31/496 ,  A61K31/502 ,  A61K31/506 ,  A61K31/519 ,  A61K31/522 ,  A61K31/53 ,  A61K31/55 ,  A61K39/39558 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28 ,  G01N33/57488 ,  A61K2039/505 ,  A61K2039/545 ,  C07K2317/76

Abstract: This disclosure is directed to compounds, compositions, and methods for the treatment of various diseases and/or conditions related to G protein-coupled receptor 174 (e.g., cancers).

公开(公告)号：US20240301499A1

公开(公告)日：2024-09-12

申请号：US18262102

申请日：2022-01-21

Applicant: Institut Gustave Roussy

Inventor： Nathalie GASPAR ,  Antonin MARCHAIS

IPC: C12Q1/6886 ,  A61K31/4409 ,  A61P35/00

CPC classification number: C12Q1/6886 ,  A61K31/4409 ,  A61P35/00 ,  C12Q2600/118 ,  C12Q2600/158

Abstract: The present invention provides tools for stratifying patients suffering from osteosarcoma, in order to identify patients having poor prognosis tumors. The invention also pertains to the use of an inhibitor of the PPARγ pathway as an antineoplastic treatment to improve the overall survival of patients with a poor prognosis osteosarcoma.

公开(公告)号：US20240182419A1

公开(公告)日：2024-06-06

申请号：US18441515

申请日：2024-02-14

Applicant: The University of Sydney

Inventor： Michael Kassiou ,  William Jorgensen ,  Lenka Munoz

IPC: C07D213/75 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4965 ,  C07D213/82 ,  C07D241/24 ,  C07D307/66 ,  C07D317/66

CPC classification number: C07D213/75 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/4965 ,  C07D213/82 ,  C07D241/24 ,  C07D307/66 ,  C07D317/66

Abstract: The present invention relates to new pharmaceutical agents, and to their use in the treatment of proliferative diseases, such as cancer (in particular, brain cancer).

公开(公告)号：US11986459B2

公开(公告)日：2024-05-21

申请号：US17713576

申请日：2022-04-05

Applicant: University of South Florida

Inventor： Bill J. Baker ,  Kyle Rohde ,  Bingjie Yang ,  Marisa Fuse

IPC: A61K31/12 ,  A61K31/133 ,  A61K31/145 ,  A61K31/192 ,  A61K31/235 ,  A61K31/343 ,  A61K31/352 ,  A61K31/365 ,  A61K31/366 ,  A61K31/4015 ,  A61K31/4045 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/454 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/505 ,  A61K31/7036 ,  A61P31/06

CPC classification number: A61K31/366 ,  A61K31/12 ,  A61K31/133 ,  A61K31/145 ,  A61K31/192 ,  A61K31/235 ,  A61K31/343 ,  A61K31/352 ,  A61K31/365 ,  A61K31/4015 ,  A61K31/4045 ,  A61K31/44 ,  A61K31/4409 ,  A61K31/454 ,  A61K31/472 ,  A61K31/496 ,  A61K31/498 ,  A61K31/505 ,  A61K31/7036 ,  A61P31/06

Abstract: The present disclosure provides methods for the treatment of infections with Mycobacterium such as tuberculosis or leprosy.